 Susan Calcaterra
Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 24 | 2024 | 515 | 8.390 |
Why?
| | Buprenorphine | 14 | 2024 | 173 | 5.910 |
Why?
| | Analgesics, Opioid | 33 | 2024 | 1002 | 4.840 |
Why?
| | Methadone | 11 | 2024 | 101 | 3.640 |
Why?
| | Hospitalization | 16 | 2025 | 2200 | 3.170 |
Why?
| | Opiate Substitution Treatment | 11 | 2024 | 155 | 3.020 |
Why?
| | Addiction Medicine | 3 | 2024 | 9 | 2.350 |
Why?
| | Hospitalists | 5 | 2021 | 245 | 2.310 |
Why?
| | Narcotic Antagonists | 7 | 2024 | 181 | 2.020 |
Why?
| | Substance Withdrawal Syndrome | 6 | 2023 | 179 | 1.760 |
Why?
| | Naltrexone | 2 | 2024 | 97 | 1.680 |
Why?
| | Alcoholism | 4 | 2024 | 809 | 1.510 |
Why?
| | Substance-Related Disorders | 8 | 2025 | 1083 | 1.480 |
Why?
| | Pain Management | 5 | 2024 | 358 | 1.250 |
Why?
| | Acute Pain | 4 | 2024 | 50 | 1.210 |
Why?
| | Qualitative Research | 8 | 2025 | 1399 | 1.150 |
Why?
| | Medical Marijuana | 2 | 2020 | 117 | 1.130 |
Why?
| | Central Nervous System Stimulants | 3 | 2015 | 161 | 1.100 |
Why?
| | Patient Discharge | 6 | 2023 | 897 | 1.090 |
Why?
| | Attitude of Health Personnel | 4 | 2024 | 1172 | 1.070 |
Why?
| | Hepatitis C | 3 | 2025 | 271 | 0.990 |
Why?
| | Drug Overdose | 6 | 2019 | 347 | 0.970 |
Why?
| | Alcohol Deterrents | 1 | 2024 | 18 | 0.900 |
Why?
| | Amphetamine-Related Disorders | 1 | 2024 | 40 | 0.860 |
Why?
| | Referral and Consultation | 4 | 2022 | 786 | 0.850 |
Why?
| | Chronic Pain | 6 | 2022 | 265 | 0.850 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2024 | 93 | 0.850 |
Why?
| | Hospitals | 7 | 2025 | 691 | 0.850 |
Why?
| | Hospital Medicine | 3 | 2022 | 89 | 0.840 |
Why?
| | Methamphetamine | 1 | 2024 | 63 | 0.840 |
Why?
| | Practice Patterns, Physicians' | 9 | 2022 | 1313 | 0.830 |
Why?
| | Humans | 60 | 2025 | 137782 | 0.800 |
Why?
| | Cause of Death | 3 | 2013 | 436 | 0.740 |
Why?
| | Liver Diseases | 1 | 2024 | 315 | 0.720 |
Why?
| | Benzodiazepines | 2 | 2022 | 155 | 0.690 |
Why?
| | Prisoners | 2 | 2014 | 149 | 0.670 |
Why?
| | Prescription Drug Misuse | 2 | 2018 | 41 | 0.670 |
Why?
| | Adult | 27 | 2025 | 38023 | 0.630 |
Why?
| | Medicine | 1 | 2021 | 121 | 0.620 |
Why?
| | Drug Substitution | 1 | 2019 | 54 | 0.620 |
Why?
| | Antiviral Agents | 1 | 2025 | 744 | 0.620 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 236 | 0.580 |
Why?
| | Internationality | 1 | 2019 | 155 | 0.570 |
Why?
| | United States | 13 | 2025 | 14870 | 0.550 |
Why?
| | Physicians | 2 | 2024 | 914 | 0.540 |
Why?
| | Healthcare Disparities | 1 | 2024 | 656 | 0.530 |
Why?
| | Health Services Accessibility | 2 | 2024 | 991 | 0.530 |
Why?
| | Poison Control Centers | 1 | 2018 | 90 | 0.530 |
Why?
| | Naloxone | 5 | 2020 | 122 | 0.500 |
Why?
| | Burnout, Professional | 1 | 2022 | 442 | 0.490 |
Why?
| | Global Health | 1 | 2019 | 386 | 0.480 |
Why?
| | Marijuana Smoking | 1 | 2019 | 256 | 0.480 |
Why?
| | Cancer Survivors | 1 | 2020 | 288 | 0.470 |
Why?
| | Middle Aged | 19 | 2025 | 33554 | 0.460 |
Why?
| | Retrospective Studies | 15 | 2022 | 15682 | 0.450 |
Why?
| | Electronic Health Records | 3 | 2022 | 1070 | 0.450 |
Why?
| | Drug Users | 1 | 2015 | 40 | 0.450 |
Why?
| | Male | 26 | 2025 | 67906 | 0.440 |
Why?
| | Female | 26 | 2025 | 73465 | 0.440 |
Why?
| | Emergency Service, Hospital | 4 | 2023 | 2072 | 0.430 |
Why?
| | Perception | 1 | 2017 | 359 | 0.430 |
Why?
| | Cannabis | 1 | 2020 | 494 | 0.390 |
Why?
| | Patient Satisfaction | 1 | 2017 | 665 | 0.390 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 807 | 0.380 |
Why?
| | Alcohol Drinking | 1 | 2019 | 828 | 0.380 |
Why?
| | Prescription Drugs | 1 | 2013 | 109 | 0.360 |
Why?
| | Databases, Factual | 3 | 2017 | 1357 | 0.350 |
Why?
| | Interviews as Topic | 3 | 2024 | 797 | 0.350 |
Why?
| | Pain | 1 | 2016 | 756 | 0.340 |
Why?
| | Cocaine | 1 | 2012 | 166 | 0.330 |
Why?
| | Mental Health Services | 1 | 2015 | 421 | 0.320 |
Why?
| | Consensus | 3 | 2025 | 683 | 0.310 |
Why?
| | Young Adult | 9 | 2024 | 13240 | 0.310 |
Why?
| | Patient Acceptance of Health Care | 1 | 2015 | 807 | 0.290 |
Why?
| | Internal Medicine | 2 | 2024 | 269 | 0.280 |
Why?
| | Inpatients | 2 | 2025 | 500 | 0.280 |
Why?
| | Inappropriate Prescribing | 2 | 2017 | 55 | 0.250 |
Why?
| | Adolescent | 9 | 2024 | 21574 | 0.250 |
Why?
| | Forecasting | 2 | 2018 | 389 | 0.250 |
Why?
| | Surveys and Questionnaires | 6 | 2025 | 5793 | 0.240 |
Why?
| | Stress, Psychological | 1 | 2014 | 1108 | 0.240 |
Why?
| | Colorado | 5 | 2019 | 4576 | 0.230 |
Why?
| | Hospitals, Psychiatric | 1 | 2024 | 26 | 0.220 |
Why?
| | Injections, Intramuscular | 1 | 2024 | 129 | 0.220 |
Why?
| | Analgesics | 2 | 2017 | 206 | 0.220 |
Why?
| | Narcotics | 1 | 2023 | 52 | 0.200 |
Why?
| | Internship and Residency | 2 | 2024 | 1151 | 0.190 |
Why?
| | Administration, Oral | 1 | 2024 | 816 | 0.190 |
Why?
| | Aftercare | 1 | 2023 | 208 | 0.180 |
Why?
| | Morpholines | 1 | 2022 | 122 | 0.180 |
Why?
| | Social Workers | 1 | 2021 | 41 | 0.180 |
Why?
| | Patients | 1 | 2023 | 175 | 0.180 |
Why?
| | Pharmacists | 2 | 2021 | 265 | 0.180 |
Why?
| | Cost-Benefit Analysis | 2 | 2023 | 593 | 0.170 |
Why?
| | Communication Barriers | 1 | 2022 | 104 | 0.170 |
Why?
| | Prescriptions | 1 | 2020 | 67 | 0.170 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 786 | 0.160 |
Why?
| | Aged | 7 | 2024 | 24001 | 0.160 |
Why?
| | Social Stigma | 1 | 2021 | 138 | 0.160 |
Why?
| | Nausea | 1 | 2020 | 111 | 0.160 |
Why?
| | Interrupted Time Series Analysis | 1 | 2019 | 68 | 0.150 |
Why?
| | Time | 1 | 2018 | 83 | 0.150 |
Why?
| | Attitude | 1 | 2020 | 259 | 0.140 |
Why?
| | Patient Preference | 2 | 2018 | 191 | 0.140 |
Why?
| | Safety-net Providers | 1 | 2019 | 119 | 0.140 |
Why?
| | Terminology as Topic | 1 | 2019 | 216 | 0.140 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2017 | 46 | 0.130 |
Why?
| | Cohort Studies | 3 | 2018 | 5750 | 0.130 |
Why?
| | Regression Analysis | 1 | 2019 | 1024 | 0.130 |
Why?
| | Counseling | 1 | 2020 | 391 | 0.130 |
Why?
| | South Carolina | 1 | 2016 | 38 | 0.130 |
Why?
| | Quality of Life | 2 | 2020 | 2894 | 0.130 |
Why?
| | Drug Utilization | 1 | 2017 | 169 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 2057 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2020 | 546 | 0.120 |
Why?
| | Mental Disorders | 1 | 2024 | 1077 | 0.120 |
Why?
| | Survival Rate | 1 | 2020 | 1973 | 0.120 |
Why?
| | Community Health Planning | 1 | 2015 | 44 | 0.110 |
Why?
| | General Practice | 1 | 2015 | 29 | 0.110 |
Why?
| | Prospective Studies | 2 | 2020 | 7623 | 0.110 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5478 | 0.110 |
Why?
| | Primary Health Care | 3 | 2023 | 1750 | 0.110 |
Why?
| | Prognosis | 2 | 2020 | 4039 | 0.110 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 307 | 0.110 |
Why?
| | Drug Prescriptions | 1 | 2016 | 245 | 0.110 |
Why?
| | Unemployment | 1 | 2014 | 43 | 0.110 |
Why?
| | Societies, Medical | 1 | 2018 | 820 | 0.100 |
Why?
| | Guideline Adherence | 1 | 2018 | 556 | 0.100 |
Why?
| | Community Health Services | 1 | 2015 | 227 | 0.100 |
Why?
| | Topography, Medical | 1 | 2013 | 10 | 0.100 |
Why?
| | Housing | 1 | 2014 | 146 | 0.100 |
Why?
| | Respiratory Insufficiency | 1 | 2016 | 318 | 0.100 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2024 | 1330 | 0.100 |
Why?
| | Washington | 1 | 2012 | 156 | 0.090 |
Why?
| | Drug Interactions | 1 | 2012 | 410 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5136 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2014 | 398 | 0.080 |
Why?
| | Risk Factors | 3 | 2018 | 10407 | 0.080 |
Why?
| | Aged, 80 and over | 2 | 2018 | 7637 | 0.080 |
Why?
| | Survival Analysis | 1 | 2012 | 1325 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1266 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2020 | 6084 | 0.070 |
Why?
| | Sex Characteristics | 1 | 2013 | 763 | 0.070 |
Why?
| | Time Factors | 2 | 2016 | 6834 | 0.070 |
Why?
| | Pregnancy | 1 | 2020 | 6771 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2015 | 3569 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2008 | 198 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1809 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 558 | 0.060 |
Why?
| | Delphi Technique | 1 | 2025 | 281 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 19 | 0.050 |
Why?
| | Life Expectancy | 1 | 2023 | 69 | 0.050 |
Why?
| | Weight-Bearing | 1 | 2003 | 173 | 0.050 |
Why?
| | Arthritis, Experimental | 1 | 2003 | 147 | 0.050 |
Why?
| | Osteoarthritis | 1 | 2003 | 185 | 0.040 |
Why?
| | Logistic Models | 2 | 2016 | 2075 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 351 | 0.040 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2018 | 33 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2019 | 135 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1586 | 0.030 |
Why?
| | Medical Audit | 1 | 2017 | 78 | 0.030 |
Why?
| | Health Transition | 1 | 2016 | 7 | 0.030 |
Why?
| | Prescription Drug Overuse | 1 | 2016 | 13 | 0.030 |
Why?
| | Medical Records | 1 | 2017 | 177 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1129 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3290 | 0.030 |
Why?
| | United States Department of Veterans Affairs | 1 | 2018 | 679 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 565 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2017 | 512 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 669 | 0.030 |
Why?
| | Health Surveys | 1 | 2015 | 514 | 0.030 |
Why?
| | Odds Ratio | 1 | 2015 | 1070 | 0.020 |
Why?
| | Program Evaluation | 1 | 2017 | 901 | 0.020 |
Why?
| | Communication | 1 | 2018 | 879 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1509 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2015 | 766 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3461 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2008 | 188 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 767 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2008 | 422 | 0.010 |
Why?
| | Iodoacetates | 1 | 2003 | 3 | 0.010 |
Why?
| | Hindlimb | 1 | 2003 | 128 | 0.010 |
Why?
| | Rats, Wistar | 1 | 2003 | 455 | 0.010 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2003 | 125 | 0.010 |
Why?
| | Proteins | 1 | 2008 | 1009 | 0.010 |
Why?
| | Acetaminophen | 1 | 2003 | 268 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2607 | 0.010 |
Why?
| | Disease Progression | 1 | 2003 | 2760 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2003 | 2836 | 0.010 |
Why?
| | Rats | 1 | 2003 | 5648 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2003 | 10837 | 0.000 |
Why?
| | Animals | 1 | 2003 | 36951 | 0.000 |
Why?
|
|
Calcaterra's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|